- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00985244
Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease (COLUMBUS)
Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
COPD is characterized by progressive development of airflow limitation that is poorly reversible. Because of a poor understanding of COPD pathogenesis, treatment is mostly symptomatic and new therapeutic strategies are limited. There is a direct relationship between the severity of the disease and the intensity of the inflammatory response.One of the hypothesis for persistent airway inflammation is that the presence of recurrent infections is responsible for this condition.
Macrolide antibiotics have a bacteriostatic as well as anti-inflammatory properties. This clinical trial will investigate whether maintenance treatment with macrolide antibiotics during 1 year in people with 3 or more exacerbations in the preceding year of inclusion can decrease the exacerbation rate in that same year of treatment.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Noord-Brabant
-
Breda, Noord-Brabant, Holanda, 4818 CK
- Amphia Ziekenhuis
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosis of COPD according to GOLD criteria (FEV1/FVC<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 ≤ 30% predicted)
- Age ≥ 18 years
- Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started
- Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period
- Informed consent
Exclusion Criteria:
- Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study.
- Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study.
- Pregnant or lactating women.
- Allergy to macrolides.
- Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).
- Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing.
- Presence of a malignancy which is clinically active.
- Bronchiectasis.
- Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment.
- Heart failure.
- Use of drugs which can adversely interact with macrolides and for which therapeutic monitoring cannot be undertaken.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: Azithromycin
Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
|
Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
Outros nomes:
|
Comparador de Placebo: Placebo
Subjects in this group will receive 3 times a week placebo
|
Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Reduction in number of exacerbations
Prazo: 1 year
|
1 year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Lung function parameters (FEV1 (L), FVC (L), FRC (L), RV (L), TLC(L), IC (L), 6 minute walking distance)
Prazo: Day 1. Also 3, 6, 9 and 12 months.
|
Day 1. Also 3, 6, 9 and 12 months.
|
|
Disease specific health related quality of life measured by St. George's Respiratory Questionnaire (SGRQ)
Prazo: Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation.
|
Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation.
|
|
Indication of anxiety and depression by Hospital Anxiety Depression Scale (HADS)
Prazo: Day 1. Also 3, 6, 9 and 12 months.
|
Day 1. Also 3, 6, 9 and 12 months.
|
|
Microbiology of sputum (culture and PCR).
Prazo: Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
|
Measurement of inflammatory markers in sputum and serum.
Prazo: Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
Day 1. Also 3, 6, 9 and 12 months. In case of an exacerbation of COPD.
|
|
Adverse events of treatment.
Prazo: Day 1. Also 3, 6, 9 and 12 months. Whenever adverse events occur.
|
Day 1. Also 3, 6, 9 and 12 months. Whenever adverse events occur.
|
|
Length of hospital stay.
Prazo: Whenever admission to hospital is required for an exacerbation of COPD.
|
Whenever admission to hospital is required for an exacerbation of COPD.
|
|
Time till next exacerbation.
Prazo: Whenever an exacerbation of COPD occurs.
|
Whenever an exacerbation of COPD occurs.
|
|
Assess type D personality by DS-14 questionnaire.
Prazo: Day 1 and month 12.
|
Day 1 and month 12.
|
|
Generic health status measured by 12-Item Short Form Health Survey (SF-12).
Prazo: Day 1, month 3, 6, 9 and 12. In case of an exacerbation.
|
Day 1, month 3, 6, 9 and 12. In case of an exacerbation.
|
|
Decrease in percentage of clinical versus outdoor department exacerbations.
Prazo: Month 12.
|
Month 12.
|
|
Effect of maintenance macrolides on intestinal bacterial restistancy patterns
Prazo: Day 1, month 6 and month 12
|
Day 1, month 6 and month 12
|
|
Serology and PCR for atypical microorganisms in serum
Prazo: day 1. In case of an exacerbation.
|
day 1. In case of an exacerbation.
|
|
Intestinal bacterial resistance patterns
Prazo: Day 1, month 6 and month 12
|
Rectal swabs will be tested for bacterial resistance patterns and change in rectal flora as a result of maintenance azithromycin.
|
Day 1, month 6 and month 12
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Joachim Aerts, MD, PhD, Amphia Ziekenhuis
- Diretor de estudo: Menno van der Eerdem, MD, PhD, Erasmus Medical Center
Publicações e links úteis
Publicações Gerais
- Djamin RS, Talman S, Schrauwen EJA, von Wintersdorff CJH, Wolffs PF, Savelkoul PHM, Uzun S, Kerstens R, van der Eerden MM, Kluytmans JAJW. Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin. Antimicrob Resist Infect Control. 2020 Jul 28;9(1):116. doi: 10.1186/s13756-020-00783-w.
- Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014 May;2(5):361-8. doi: 10.1016/S2213-2600(14)70019-0. Epub 2014 Apr 15.
- Uzun S, Djamin RS, Kluytmans J, Van't Veer NE, Ermens AA, Pelle AJ, Mulder P, van der Eerden MM, Aerts J. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Trials. 2012 Jun 9;13:82. doi: 10.1186/1745-6215-13-82.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Amphia-ABR29500
- 2009-015857-19 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em DPOC
-
Fraunhofer-Institute of Toxicology and Experimental...Institute for Pharmacology and Toxicology, RWTH AachenConcluídoVoluntários Saudáveis | COPD GOLD I a IV | Asma GINA 1 a 4Alemanha